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Short interfering RNAs (siRNAs) trigger RNA interference (RNAi) both in vitro and in vivo, 
where the expression of the encoded protein is silenced. Its potential use as a therapeutic 
agent is limited by its rapid enzymatic degradation and low cellular uptake. Therefore, a 
delivery carrier is desired to increase its solution stability and improve cellular uptake. In this 
study, Arginine-9 (R9), a cell penetrating peptide derived from the HIV 1 Tat protein, was 
investigated as a potential carrier for siRNAs at pH 7.3. The optical activity of siRNA 
decreased with increasing R9 concentration, with only 7.8±3.8% of the initial absorbance at 
260nm remained at siRNA saturation.  The highest binding ratio of R9 to siRNA determined 
from the UV/Vis spectra was 10.3:1 (corresponds to a charge ratio of 2.2:1 (+/-)).  The 
measured hydrodynamic diameter increased with increasing R9, with a maximum value of 
~1μm at siRNA saturation.  At R9 to siRNA charge ratios below 5.74:1, the surface charge 
of the complexes increased rapidly with the addition of R9.  However, the rate of increase of 
Zeta potential decreased significantly with subsequent addition of R9. At charge ratio above 
1.43:1, the complexes expressed low surface charge which led to the formation of aggregates 
in solution.  A new peptide library was designed which utilized several properties of known 
cell penetrating peptides. In vitro siRNA transfection of eGFP siRNA with C166-GFP cells 
was used to determine the transfection efficiency of the new peptides. Preliminary results of 
the newly designed peptides showed that some of them are not as effective when compared 
to Lipofectamine 2000 (Invitrogen). However, this experimental protocol can be extended to 
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Chapter 1 
Introduction 
Short interfering RNA (siRNA) and various types of nucleic acid (NA) based drugs, such as 
plasmid DNAs and oligonucleotides, have shown promising therapeutic potential with 
several ongoing clinical trials [1] but lacked a suitable formulation to achieve high delivery 
efficiency and potency. When administered, a significant portion of these NA based drugs 
are excreted through the reticuloendothelial system (RES) mainly due to their small size and 
hydrophilicity. Furthermore, they are subjected to enzymatic degradation during circulation 
and within the cell. As a result, the potency of these drugs is decreased, and in some cases an 
increase of drug dosage is required to compensate these effects. Since NA drugs function in 
the cytosol or the nucleus, the inability of hydrophilic drugs to effectively travel across the 
hydrophobic core of the plasma membrane, and sometimes the nuclear membrane, is another 
major obstacle for their therapeutic application. If the drug does not bear a cell-specific target 
moiety, it can potentially be taken up by all cells and may cause unwanted side effects when 
accumulated at non-targeted sites.  
 
In order to overcome these challenges, several methods have been developed to increase the 
delivery of NAs. For instance, structural modification of the phosphodiester backbone of the 
NAs can be applied to increase the stability of the NAs against nucleases [2], thus to prolong 
the circulation half-life of the drug. In addition to various established delivery methods, the 
carrier mediated delivery of siRNA has received increasing attention recently. Peptides, due 
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to their biodegradability, biocompatibility, and versatility have a very promising potential to 
be used as a carrier for siRNA delivery. 
 
1.1 RNAi and siRNA 
Various enzymes and structural components in a cell are proteins, which are genetically 
encoded by the DNA.  The first step of protein production is the transcription of DNA which 
yields messenger RNAs (mRNAs).  Messenger RNAs are then being translated to proteins 
within the ribosome.  The freshly produced protein will go through the cell’s regulatory 
process, and fold to obtain its functional conformation, which can be assisted by molecular 
chaperones.   
 
RNA interference (RNAi) is an evolutionary conserved mechanism that performs a sequence 
specific, post transcriptional gene silencing (PTGS) through the use of short RNAs.  RNAi is 
first identified in C. elegans by Fire and Mello [3].  RNAi can be triggered by several sub-
type of short RNAs, which include short interfering RNA (siRNA), micro RNA (miRNA),  
tiny non-coding RNA (tncRNA), small modulatory RNA (smRNA), and short hairpin RNA 
(shRNA) [4,5]. Double stranded RNA (dsRNA) can act as a precursor of RNAi in 
invertebrates to obtain siRNAs upon its cleavage by the Dicer.  However, dsRNA triggers 
interferon response in vertebrates [5], which prevents its use in therapeutic applications.   
 
Short interfering RNA is a double stranded RNA with 21-22 nucleotides in length.  Two 
nucleotides on the 3’ end on both the sense and anti-sense strands are overhanging (Figure 
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1-1).  Short interfering RNA is either the product of the enzymatic cleavage of long dsRNA 
by the dicer, or can be produced synthetically [5].   
  
 
Figure 1-1. An illustration of a siRNA with 21 base pairs and a two nucleotide overhang at 
the 3’ end.   
(Reference: Dykxhoorn. 2003. Nature Revs. Mol. Cell. Biol.) 
 
1.2 Mechanisms of RNAi  
Once the siRNA is located in the cytosol, Ago2 cleaves the sense strand of the siRNA [6,7]. 
Further, since the 5’of the anti-sense strand is less thermodynamically stable then the 5’ of 
the sense strand [8], the anti-sense strand will be thermodynamically favored to incorporate 
to the RNA induced silencing complex (RISC).  The anti-sense sequence of the siRNA that is 
incorporated into the RISC would pair with its complementary mRNA sequence (Figure 1-2).  
The mRNA is then cleaved enzymatically by Ago2.  Since the cleaved RNA fragments lack 
either the cap structure m7G or the polyA tail, which are essential to RNA stability, this leads 
to further degradation of the mRNA molecule.  Since mRNA is the precursor to protein 
translation, the protein encoded by such mRNA thus cannot be synthesized. Gene silencing 
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by RNAi is also referred to as post-transcriptional gene silencing (PTGS) because the 
silencing takes place after transcription and before translation.   
 
 
Figure 1-2. Gene silencing by siRNA. Long double-stranded RNA is cleaved by Dicer.  The 
resulting siRNAs is then incorporated to the RNA induced silencing complex (RISC).  Upon 
separation and cleavage of the sense strand, the anti-sense strand then guides the RISC to the 
complementary mRNA. The target mRNA is then cleaved and degraded.  




1.3 Carrier Mediated siRNA Delivery 
Recently, the carrier-mediated delivery system has become a prevalent approach for 
improving the cellular delivery of nucleic acids (NAs). The carriers, self-associated or 
covalently conjugated with the NAs, are designed to prolong drug circulation time, to 
improve membrane permeation, and increase cell targeting capabilities, while being 
biocompatible and biodegradable. A safe drug delivery system should exert minimal side 
effects, that is, minimal cytotoxicity and inflammatory response, especially to non-targeted 
cells. Hydrophobic or highly charged particles can interact with opsonins, where the resulting 
complexes are removed from circulation by phagocytes and the reticuloendothelial system 
(RES) [9,10], which essentially decreases the effective drug concentration. Neutrally charged 
particles are found with a lower opsonization rate than charged particles due to decrease in 
electrostatic interactions with opsonins [9,11]. Complex size also has an effect on the rate of 
opsonization. In addition, smaller carrier-drug complexes, which have a smaller surface area, 
display slow opsonization and thus a longer bloodstream circulation time [10]. Since many 
carrier-drug complexes are mainly internalized through the temperature and energy 
dependent endocytosis pathways (Figure 1-3), small complexes with size 100-200 nm will 
facilitate cellular internalization [9,11]. Upon cellular internalization, the concentration of 
various enzymes within the vesicle increases and the pH is about 5.0 during the transition 
from early to late endosomes. The increase in enzymatic degradation and acute pH changes 
would decrease the drug potency if the carrier cannot escape from or withstand the harsh 
environment within the late endosome, or later in the lysosome. Recently, molecules such as 
the amino acid histidine, that has a pKa close to the range of 5 to 7, have been used as a 
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“proton sponge” to minimize the pH changes as well as induce leakage in the late 
endosome/lysosome [12,13].  
 
In order to achieve cellular targeting, specific molecules, such as antibodies, that can interact 
with surfaces of the targeted cells, can be grafted onto the surface of the carrier-drug 
complexes [14,15]. For passive cellular targeting, the carrier-drug complex should exhibit 
physiochemical properties similar to the targeting site, such that it can easily diffuse to the 
targeted cells [16,17]. Release kinetics of the drug from the carrier-drug complexes is another 
essential aspect in the carrier design. It is desirable to have high drug packing density within 
the complex, where the drug can be released in a controllable manner that is below the toxic 
concentration but above the minimum therapeutic concentration. Thus, the determination of 
size, surface charge and surface chemistry is essential when characterizing the 






Figure 1-3 Nucleic acid-carrier complexes internalized through endocytosis. The complexes 
are first associated to the surface of the cell membrane (1), and they are then internalized by 
endocytosis (2). The carrier then mediates the escape from the endosome into the cytoplasm. 
Endosomal escape of the complexes is initiated by the intrinsic membrane permeability of 
the carrier or acquired membrane permeability due to pH sensitivity (3, 4). For complexes 
that fail to escape the endosome are degraded in the lysosome (5). Depending on the type of 
genetic material, the nucleic acids are then translocated to the nucleus for transcription (6), or 






















The objectives in this research were:  
• To study the concentration effect on the complexation between a cell penetrating 
peptide R9 and a model siRNA. 
• To characterize the siRNA-R9 complexes in terms of size and surface charge at 
various siRNA/R9 ratios. 
• To elucidate the forces associated with the interaction between siRNA and R9. 
• To design new peptides as carriers for effective siRNA delivery 







2.1 Existing Nucleic Acid Delivery Technologies 
Various types of carriers have been developed to improve the delivery of NAs. The carrier 
mediated approach is appealing since a vast variety of materials can be used and each can be 
engineered to obtain the desired properties. The materials used in the carrier-mediated 
delivery range from lipids [20-27], peptides [28-31], polysaccharides [32], synthetic [33-37] 
and natural polymers [38], gold [39,40], ceramics [41], to virus capsids [42]. They are mainly 
in the form of liposomes [20-27], micelles [43-47], dendrimers [48], emulsions [49], 
microemulsions [50-54], hydrogels [40], micro/nano-tubes [55,56], micro/nano-capsules [57-
62], nanocrystals [21] and conjugates [63-65]. Furthermore, the various materials can be used 
in combination[40,66-68] with various biological constructs, such as antibodies and ligands, 
to further improve the biostability and targeting ability of the drug system [67,69,70]. 
 
2.1.1 Viral Carriers 
To date, the viral delivery system can achieve the highest delivery efficiency. A virion is 
made up of genetic materials protected by a protein coating, which is referred to as capsid. 
Virus capsids or virus-like particles are made up of multiple copies of one or a few proteins. 
These materials have defined structures, are easy to produce and are homogeneous in size. 
Drug particles can be loaded within the capsid or grafted on the exterior. As well, various 
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molecules such as antibodies, fluorophores, and peptides can be conjugated to specific 
locations on the capsid surface for cell targeting, to act as probes, or to improve solution 
properties of carrier-drug complexes [71]. Various viral carriers have demonstrated high drug 
delivery efficiency in vitro, but were found to be cytotoxic in a number of in vitro, in vivo 
and clinical studies [72]. The new generation of adenoviral vectors, where all viral coding 
genes are removed, have shown high transfection efficiency with significantly reduced 
cytotoxicity [73].  
 
2.1.2 Liposomes 
With several formulations already approved by the FDA [74], the lipid-based carrier system 
represents a mature technology and is a relatively simple and reliable method for drug 
delivery in vitro. Each lipid molecule consists of a hydrophilic head and a hydrophobic tail, 
where the hydrophilic head can be positively, negatively, or neutrally charged. Some 
common lipids used as drug carriers are DOTAP, DOPC, and DOPE. When suspended in 
solution, the lipid based carrier can form liposomes, which are lipid bilayer vesicles. The 
liposome based delivery system is very efficient in entrapping hydrophobic drugs in the 
hydrophobic region in the bilayer [75].  Depending on the solubility of the drug in the 
hydrophobic region of the liposome, the entrapping efficiency [76] of the drug at a specific 
carrier concentration can be as high as 100% [75]. Hydrophilics drugs, such as NAs, are 
associated with liposomes mainly via electrostatic interaction with the charged head group. 
The entrapping efficiency of liposomes for hydrophilic drugs is lower when compared to 
hydrophobic drugs (~30%), but can be increased by various physical and chemical methods, 
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such as using freeze drying and pH gradient [75]. However, highly charged liposomes often 
interact with serum proteins and trigger complement activation; subsequently they are 
cleared out by phagocytes and the RES rapidly [77]. Complement activation can be reduced 
by lowering the liposome concentration. However, at a low and non-toxic liposome 
concentration, the effective drug concentration is often too low or the transfection efficiency 
is only slightly better than naked drugs [77]. In general, neutrally and negatively charged 
liposomes are less cytotoxic due to decreased interactions with serum proteins. However, 
cationic liposomes can express substantially higher transfection efficiency than the neutrally 
or negatively charged liposomes. Therefore, surface modifications of liposomes, such as 
PEGylation, are used to decrease complement activation. When grafted on liposomes, PEG 
increases the hydrodynamic volume that protects the liposome and the drug from clearance, 
complement activation, and enzymatic degradation [74,78-80]. When administered 
intravenously, liposomes have a tendency to be taken up by the lungs and liver. The limited 
biodistribution offers an opportunity to exploit the use of liposomes for targeted delivery to 
the lungs [81,82] and liver [78,83], however this also limits the bioavailability of liposome 
enclosed drugs in other areas. Although with numerous successes in vitro, due to its 
instability, cytotoxicity, and poor biodistribution, lipid based carriers have encountered 
difficulties in various in vivo and clinical studies [79,84]. 
 
2.1.3 Polymeric Carrier 
Synthetic and natural polymers have been used as carriers for various drug molecules. 
Polymers are macromolecules made up of repeated units of covalently bonded monomers. 
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Some synthetic polymers are biodegradable, such as poly(ortho ester)s and poly(amino 
acid)s, and some are not, such as silicone elastomers, and poly(ethylene glycol) (PEG). 
Natural polymers such as chitosan, dextran and albumin can also be used as drug carriers. 
Polymers have a variety of three-dimensional structures which range from linear, branched, 
cross-linked, to dendritic. (Figure 2-1) The different types of monomers in a heterochain 
polymer can be arranged to give additional structural varieties such as blocks and grafts. The 
versatility in chemical structure provides excellent foundation for the design of the polymeric 
drug carrier. For example, polymeric micelles [37,44-46,85], di- or tri-block copolymers [34-
37], and dendritic polymers [86,87] have been investigated. In particular, PEG is one of the 
most frequently used polymers for drug delivery. PEG has high water solubility, 
biocompatibility and chain flexibility. PEG has minimum interaction with serum proteins; 
thus it provides “stealth” from opsonins and phagocytes to the carrier it is associated with. 
Subsequently, PEG conjugated drugs and PEG coated carrier-drug complexes have shown 
longer circulation half-lives [67,88-91]. PEG has been approved by the FDA for use in 
various carrier mediated drug formulations, foods, and cosmetics [88]. Poly (L-Lysine) 
(PLL) has also been used as a carrier for genetic materials [48,92]. The positively charged 
lysine residues from PLL can electrostatically interact with the negatively charged phosphate 
groups in nucleic acids, forming PLL-NA complexes. PLL in various structures has been 





Figure 2-1 Schematic of Polymer Structures: Linear (Top left), branched (top right), cross-
linked (bottom left), and dendritic (bottom right). 
 
2.2  Peptide Mediated Drug Delivery 
Peptides are short sequences of amino acids covalently linked through a peptide bond. 
Usually with 30 or less amino acids, peptides represent a very promising drug carrier 
material, which has received increasing attention since the 1990s. The rationale for peptide 
mediated NA delivery evolved from the biochemical knowledge that the active sites of 
enzymes, receptor ligands and antibodies involve about 5 to 20 amino acids. Thus, it should 
be possible to use small synthetic peptides to emulate the active sites of proteins and 
formulate synthetic DNA complexes that are, for example, as efficient as viruses, but do not 
have their limitations. Numerous peptides investigated as a NA carrier are of biological 
origin. For instance, cell penetrating peptides (CPPs), fusogenic peptides, nuclear uptake 
peptides, and receptor-based targeting peptides are derived from existing cellular or viral 
proteins. One advantage of using synthetic peptide is the readily and accurate determination 
… … 
… … 
… … … … 
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of its molecular structure and purity. Due to its biological origin, it is biodegradable and 
more likely to be biocompatible. Furthermore, through the use of the 20 naturally occurring 
amino acids, each with different hydrophobicity, size, and other solution properties, the 
chemical and structural design of peptide carriers is highly versatile. The versatility of 
peptide carrier design also provides an opportunity for the synthesis of multifunctional 
reagents that can improve stability, transfection, and targeting ability. This approach is 
necessary to provide a rational basis, rather than an empirical one, on which significant 
improvements can be made in the delivery systems.  
 
Peptide based carriers have successfully delivered hydrophobic molecules, proteins, and 
genetic materials in various in vitro / in vivo studies [28,30,66,96-100].  Certain synthetic 
peptide derivatives, such as D-amino acids [101], β-amino acids [102], peptoid [101] and 
carbamate [103] have also been studied and have shown superior transfection abilities when 
compared to natural peptides. (Figure 2-2) Depending on the primary structure and the 
solvent, a peptide can attain secondary structures such as α-helix or β-pleated sheet, similar 
to those found in proteins. The importance of α-helical [97,104] and β-pleated sheet [105-
107] structures to membrane translocation have been acknowledged in some studies. For 
example, the membrane translocation properties of two primary amphiphilic peptides [Pα] 
and [Pβ] were studied [108], where the former has an α-helical structure and the later has a 
β-sheet structure. It is found that both peptides are capable of membrane insertion; however 
in their preliminary studies, only the siRNA delivered by [Pβ] is capable of inducing 
silencing activity. The difference in the transfection ability among the two peptides is 
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possibly due to the higher availability of hydrogen bonding sites in the β-strand whilst most 
of the hydrogen-bonding sites are occupied within the α-helical peptide. Despite the 
importance of the peptide secondary structure in drug delivery, it is not the only factor that 
determines cellular uptake of drug molecules since some peptides in the random coil 
conformation, such as oligoarginine, can also deliver drugs across the cell membrane 
[109,110]. 
 
In general, cellular uptake can either be energy dependent or independent.  Other than 
macrophages, the energy dependent pathways for cells generally include macropinocytosis, 
clathrin-mediated endocytosis, and caveolin-mediated endocytosis [111].    On the other 
hand, the possible energy independent cellular uptake mechanisms include the inverted 
micelle, barrel stave, toroidal pore, and carpet models [112]. (Figure 2-3)  In the inverted 
micelle model, the peptide first associate with the bilayer surface through electrostatic 
interaction.  The lipid bilayer reorganizes itself to minimize the exposure of the complex to 
the solvent, which eventually leads to the formation of an inverted micelle in the bilayer and 
is later released to the cytosol. (Figure 2-3A)  It has been proposed that peptides can behave 
similar to membrane proteins, where pores are resulted when the amphiphilic peptides embed 
in the lipid bilayer as cylindrical pores.  A barrel stave is resulted when the outer surface of 
the pore is hydrophobic, thus interacting with the hydrophobic core of the bilayer. (Figure 2-
3B) In contrast, a toroidal pore is resulted when the surrounding of the pore is hydrophilic 
and interacts with the hydrophilic heads of the bilayer. (Figure 2-3C)  In the carpet model, 
the peptide first associates with the membrane surface, then the basic residues trigger 
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reorganization of the membrane structure, which eventually leads to transfer of extracellular 
materials into the cytosol. (Figure 2-3D)  
 
    




Figure 2-3: Schematic representing possible cellular uptake mechanisms: inverted micelle 




A B C D
 
17 
2.2.1 Cell Penetrating Peptides Derived from Proteins 
Although the cell membrane acts as a highly selective barrier to foreign materials, many 
viruses possess proteins that are able to perturb the cell membrane and release their contents 
into cells. A number of peptide carriers were derived from these viral proteins, where they 
are the shortest peptide sequences responsible for cell penetration (also referred to as the 
minimum effective peptide sequences). These peptides such as Tat and Penetratin are 
referred to as cell penetrating peptides (CPPs) or protein transduction domains (PTDs). They 
have shown high cell penetration ability in various in vitro / in vivo investigations 
[29,30,96,114,115]. Some protein-derived CPPs are given in Table 2-1. Although the 
internalization mechanisms are not well-defined for the majority of CPPs, recent research has 












Table 2-1 Sequences of naturally occurring cell penetrating peptides (CPPs) 
Peptide Origin Sequence Ref. 
adenoviral core 
peptide μ (mu) 
Adeno virus MRRAHHRRRRASHRRMRGG [118] 
Caiman crocodylus 
Ig(v) light chain 
 MGLGLHLLVLAAALQGA [119] 
E5 Influenza virus GLFEAIAEFIEGGWEGLIEG [120] 
E5CA Influenza virus GLFEAIAEFIEGGWEGLIEGCA [121] 
E5WYG Influenza virus GLFEAIAEFIEGGWEGLIEGWYG [122] 
gp41 fusion sequence  GALFLGWLGAAGSTMGA  
H5WYG Influenza virus GLFHAIAAHFIHGGWHGLIHGWYG [123] 
HA Influenza virus GLFEAIAGFIENGWEGMIDG [124] 
  GLFEAIAGFIENGWEGMIDGWYG  [125] 
HBV-PreS2/TLM  PLSSIFSRIGDP [126] 
hCT derived peptide  LGTYTQDFNKFHTFPQTAIGVGAP [127] 
Human b3 integrin 
signal sequence 
 VTVLALGALAGVGVG  
INF-1 Influenza virus GLFEAIAGFIENGWEGMIDGGGC [128] 
INF-7 Influenza virus GLFEAIEGFIENGWEGMIDGWYG [128] 
K5 Influenza virus GLFKAIAKFIKGGWKGLIKG [120] 







growth factor (K-FGF) 
AAVALLPAVLLALLAP, AAVLLPVLLAAP [129], 
[130] 
PDX-1  RHIKIWFQNRRMKWKK [131] 
Penetratin (43-58) Antennapedia RQIKIWFQNRRMKWKK [132] 
Prion protein  N-terminal (1-28) [133] 
pVEC  LLIILRRRIRKQAHAHSK-amide [134] 
SynB1 Protegrins RGGRLSYSRRRFSTSTGR [135] 
Tat (48-60) HIV-1 GRKKKRRQRRRPPQ [136] 
VP22  DAATATRGRSAASRPTERPRAPARSASRPRRPVD [106] 
 
 
Tat, a trans-activating transcriptional activator of HIV-1, is one of the most studied among all 
protein derived CPPs. The Tat protein has 86 amino acids but only the cluster of basic amino 
acids RKKRRQRRR, starting from amino acid residue 49 to 57 is responsible for the cell 
penetrating property of the Tat peptide [136]. Each Tat peptide has eight positive charges, 
resulting from two lysines and six arginines. Due to charge repulsion, the Tat peptide remains 
as a random coil in solution [137]. The Tat peptide has successfully delivered fluorophores 
[96], peptides [30], proteins [28,138] and oligonucleotides [139] in various in vitro [115], ex 
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vivo [96], and in vivo [28,96] models. Recent research has shown that Tat enters the cell 
mainly through adsorptive endocytosis [140]. Due to the presence of cationic residues, the 
CPP is first adsorbed onto the negatively charged cell surface through electrostatic 
interaction, before being internalized through several types of endocytosis, such as clathrin-
dependent endocytosis [140], caveolin-dependent endocytosis [141], and raft-dependent 
macropinocytosis [142]. 
 
The Antennapedia (Antp) protein is a membrane transduction protein that corresponds to the 
transcription factor of Drosophila. Penetratin, the minimal effective sequence for cell 
penetration, is the third α-helix from Antp (amino acid residues 43-58) [143]. Penetratin is α-
helical in hydrophobic environment but it has no specific secondary structure in aqueous 
solution [143]. However, the α-helical structure is not essential to membrane translocation 
since point mutation with proline, which disturbs secondary structures, did not prevent the 
internalization of Penetratin [143]. Further experiments have shown that the basic amino 
acids and the tryptophan residue at position 6 of the peptide (48 of Antp) are essential to the 
uptake of Penetratin [132,144]. Recent confocal laser scanning microscopy and flow 
cytometry experiments have shown that the Penetratin has very low lipid vesicle permeability 
and that uptake in vitro is temperature and ATP dependent [114,145,146]. Based on these 
results, Penetratin was suggested to be taken up through the endocytic pathways but not the 




2.2.2 Cationic Peptides 
The oligomers of the four cationic amino acids, lysine, arginine, histidine, and ornithine can 
translocate through the cell membrane and be localized in the cytosol and the nucleus [147]. 
Basic amino acids, such as lysine and arginine, are positively charged in physiological pH; 
thus they can interact with negatively charged drug molecules or cell membrane through 
columbic interactions.  
 
The transfection efficiency of therapeutic materials delivered by oligolysine is generally low 
[147], because highly charged oligolysine are rapidly removed from circulation in the RES.  
Various methods have been employed to increase its efficiency. For example, Adami and 
Rice [148] have used a cysteine containing, lysine-rich-peptide (CWK18), which allows the 
formation of disulfide bond between peptide molecules in an oxidation condition. Complex 
stability is improved upon disulfide bond formation induced by glutaraldehyde. Later, 
McKenzie, Kwok, and Rice [149] have shown that these disulfide-crosslinked complexes are 
smaller in size, and display slower opsonization rate, when compared with uncross-linked 
complexes. The in vitro transfection efficiency of such a complex is found to be higher since 
the release of DNA is only triggered by disulfide bond reduction in the cytosol. Highly 
charged oligolysine often interacts with serum proteins which decreases its efficiency. It is 
found that the transfection efficiency can be increased by conjugating oligolysine with PEG 
[94]. In addition, the transfection efficiency of oligolysine-complexes is limited by poor 
endosomal escape [92], which has been improved recently by facilitating endosomal escape 
or bypassing the endosomal pathway [150-152]. For example, histidine residues have been 
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used to enhance endosomal escape due to their protonation upon decreasing in pH. Histidine-
containing oligolysine has shown higher transfection efficiency in vitro [153].  
 
Six out of the 13 amino acids in the cell penetrating peptide HIV-1 Tat are arginines [136]. 
Oligoarginine is a derivative of the Tat peptide that has preserved the cell penetration 
property of the Tat peptide. The chain length effect of oligoarginine has been investigated by 
two research groups [101,154].  In general, the cell penetration capability of oligoarginine 
requires a minimum chain length of four to five arginine residues and that decaarginine gives 
the maximum translocation efficiency. The translocation efficiency decreases when the chain 
length is further increased. In another study, the authors have investigated the effect of 
spacing between arginine segments in a peptide with seven arginines and three non basic 
amino acid residues [155]. The sample peptides always perform better in cellular 
internalization when compared with the heptaarginine, which suggest that not only the 
number of arginines present is important, but also the spacing between arginine residues. It is 
believed that the spacing between arginine residues provide structural flexibility to the 
functional group, which eventually leads to an increase in translocation efficiency.  
 
2.2.3 Designed Amphiphilic Cell Penetrating Peptides  
Since the amphiphilic lipid bilayer is the major component of a cell membrane, it appears 
feasible to use an amphiphilic peptide to carry a drug across the cell membrane, where one 
can expect that the hydrophilic section of the peptide first interacts with the membrane 
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surface with subsequent translocation to the cytosol assisted by the hydrophobic section of 




Table 2-2 Sequences of synthetic cell penetrating peptides 
Names Sequence Type of 
Amphiphilicity 
Reference 
6 MGLGLHLLVLAAALQGAKSKRKV  Primary [156] 
[1], A, SP, 3  MGLGLHLLVLAAALQGAWSQPKKKRKV  Primary [156-159] 
[2], X, 4  MGLGLHLLVLAAALQGAKKKRKV  Primary [156,159] 
[3], FP, B, 1  GALFLGWLGAAGSTMGAWSQPKKKRKV  Primary [156-159] 
[4], 2  GALFLGWLGAAGSTMGARKKKRKV  Primary [156,159] 
[5], MPG_NLS GALFLGFLGAAGSTMGAWSQPKSKRKV  Primary [159,160] 
5, SP-NLS  MGLGLHLLLAAALQGAKKKRKV  Primary [156,161] 
Bc  GALALGALGAAGSTMGAWSQPKKKRKV  Primary [157] 
FP1, Ba, MPG  GALFLGFLGAAGSTMGAWSQPKKKRKV  Primary [160] 
FP2, Bb  GALFLGFLGAAGAAMGAWSQPKKKRKV  Primary [157,158,160]
FP3 GALALGLLGAAGSTMGAWSQPKKKRKV  Primary [157,158] 
FP4, Bd  GALFLAFLAAALSLMGLWSQPKKKRKV  Primary [158] 
GALA  WEAALAEALAEALAEHLAEALAEAEALEALAA Secondary [157,158] 
gp41 fusion sequence  GALFLGWLGAAGSTMGA Primary [162] 
JTS-1  GLFEALLELLESLWELLLEA  Secondary [163] 
KALA  WEAKLAKALAKALAKHLAKALAKALKACEA  Secondary [163] 
Model amphiphilic 
peptide (MAP) 
KLALKLALKALKAALKLA  Secondary [164] 
MPS (human integrin β3 
signal sequence)  
VTVLALGALAGVGVG   [165] 
MPS (kaposi FGF signal 
sequence)  
AAVALLPAVLLALLAP   [129] 
MPS (kaposi FGF signal 
sequence)  
AAVLLPVLLAAP   [166] 
P3  VAYISRGGVSTYYSDTVKGRFTRQKYNKRA  [167] 
Pep-1  KETWWETWWTEWSQPKKKRKV  Primary [167] 
PreS2-TLM  PLSSIFSRIGDP   [105] 
SPM  MGLGLWLLVLAAALQGAKKKRKV  Primary [168] 
SV40 (T-antigen NLS) PKKKRKV  [134] 
Transportan  GWTLNSAGYLLGKINLKALAALAKKIL  Primary [169] 
43 LARLLARLLARL Secondary [97] 
43S LARSLARSLSRL Secondary [97] 
46 LARLLARLLARLLRALLRALLRAL Secondary [97] 
46S LARSLARSLSRLLRSLSRALSRAL Secondary [97] 
46P LARLLARLLARPPRALLRALLRAL  [97] 
[Pa] GALFLAFLAAALSLMGLWSQPKKKRKV Primary [108] 
[Pb] GALFLGFLGAAGSTMGAWSQPKKKRKV Primary [108] 
Hel 13-5 KLLKLLLKLWLKLLKLLL Secondary [170] 
Hel 11-7 KLLKLLLKLWKKLLKLLK Secondary [170] 





There are two major types of amphiphilic cell penetrating peptides, namely primary and 
secondary amphiphilic peptides. Primary amphiphilic peptides have specific hydrophobic and 
hydrophilic domains joint by a linker in the primary sequence (Figure 2-4). The hydrophobic 
region can interact with hydrophobic drugs and anchor itself in the cell membrane. The 
hydrophilic region, on the other hand, interacts with hydrophilic drugs and the cell membrane 
surface through electrostatic interactions. In general, the primary amphiphilic peptides adopt 
a random coil structure at neutral pH but a defined secondary structure upon a change in pH 
or interaction with the cell membrane [105,116]. The high efficiency of primary amphiphilic 
peptides may be attributed to the change in secondary structure at low pH, which can induce 
leakage of the endosomal membrane and facilitate endosomal escape of carrier-drug 
complexes. One example of primary amphiphilic cell penetrating peptide is MPG [105]. It 
consists of a hydrophobic domain derived from a fusion sequence and a nuclear localization 
sequence, joint through a linker. MPG changes its conformation from random coil to β-sheet 
structure when interacting with the cell membrane. It is proposed that MPG achieves cell 
penetration through the formation of pores on the cell membrane.  
 
 
Figure 2-4 Schematic of a Primary Amphiphilic Peptide. The hydrophobic and hydrophilic 







On the other hand, when the amphiphilic nature of the molecule is originated from its 
secondary structure, that is α-helix or β-sheet structures, it is referred to as secondary 
amphiphilicity (Figure 2-5). Many peptide delivery carriers are designed based on α-helix 
amphiphilicity [97,108,170] while investigations based on amphiphilic β-sheet peptides are 
very limited [108,171]. For secondary amphiphilic peptides, two equilibrium states can exist 
for its interaction with cell membrane. (Figure 2-6) Secondary amphiphilic peptides can be 
embedded in the cell membrane so that the hydrophobic side is anchored in the hydrophobic 
core of the bilayer and the hydrophilic side interacts with the hydrophilic heads of the lipid 
bilayer. Alternatively, the peptides can first form micelles or aggregates to minimize the 











Figure 2-5 Schematics of secondary amphiphilic peptides. (left) Hel 9-9 forms an α-helix 
with a hydrophilic side (grey circles) and hydrophobic side (white circles) consisting of 
lysine and leucine, respectively [97]. (right) EAK16-II adopts a β-sheet conformation 
consisting of hydrophobic alanines (patterned rectangles) and hydrophilic lysine (+) and 
























Figure 2-6: This figure outlines a proposed hypothetical model of interaction between an 
amphipathic peptide in two equilibrium states (micelles and single molecules) and a 
membrane model. The circles represent a frontal view of molecules of an amphipathic 
peptide (the yellow parts correspond to the hydrophobic part of the molecules and the blue 
parts correspond to hydrophilic parts. The polar heads of the phosphatidylcholine bilayer are 
represented by light blue circles whereas the hydrophobic tails are black). Single molecules 
of peptide insert into the outer layer of the bilayer by mean of hydrophobic interactions (a), 
while in (b) the hydrophilic outer parts of the micelles interact with the hydrophilic 
macromolecules or phospholipids heads [116]. 
 
 
The interaction between oligonucleotides and peptides from a group of amphiphilic α-helical 
peptides were being investigated and it was found that these peptides are able to bind to 
oligonucleotides and form aggregates [172]. These amphiphilic α-helical peptides display 
low cytotoxicity. However, the transfection efficiency of 46, which shows the best result 
among the group, is still 3-5 times lower than the liposome based carrier Lipofectin 
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(Invitrogen). GALA and KALA are two examples of α-helical amphiphilic peptides. In 
particular, GALA can form a helical structure corresponding to a decrease in pH, in which 
the glutamic acids (pKa~4.2) are protonated [173]. The transition to an α-helix enables the 
peptide to disrupt the endosomal membrane so that the drug cargo is released into the 
cytosol. However, GALA does not have any cationic residues to self-associate with NAs. 
KALA has a sequence similar to GALA, where some aniline residues are replaced with 
lysine and the number of glutamic acid residues is reduced [174]. KALA has preserved the 
cell penetration property of GALA and is able to translocate across the cell membrane when 
complexed with NAs [173]. 
 
2.3 Preparation of peptide-NA nanoparticles 
In carrier mediated NA delivery, the carrier-NA nanoparticles can be formed by conjugation 
where the two molecules are covalently linked together. Several options are available for 
covalent conjugation of peptides to NAs, including the use of cross-linking agents, triple-
helix-forming oligonucleotides, and attachment to the ends of linear NAs. The type and 
length of covalent linker should be considered carefully, as the appropriate spacer length and 
chemistry are critical to allow intracellular recognition and activity of the NAs. Normally 
conjugation of peptides to NAs involves formation of a disulfide bond, which can be rapidly 
cleaved in the reducing environment of the cell. It is not yet clear whether use of cleavable 




Another common method to form carrier-drug nanoparticles is through molecular self-
association, where it is usually driven by hydrogen bonding, electrostatic and/or hydrophobic 
interactions. In comparison to chemical modifications of the phosphodiester backbone, which 
is time-consuming and costly [176], carrier-drug complexes formed by the binding of 
peptides to the NAs may provide a simple and fast means to protect the NAs from 
degradation. Many positively charged peptides can interact with the negatively charged 
phosphate backbone of NAs through electrostatic interactions. In this case, the stoichiometry 
of complexation may affect cellular uptake. In the consideration of self-associated peptide-
NA complexes, the incorporation of NAs with peptides is one of the most critical steps in the 






Physicochemical Characterization of siRNA-Peptide Complexes 
In the search of a suitable formulation for peptide mediated siRNA delivery systems, it is of 
our interest to characterize a model siRNA-peptide complex using various physicochemical 
methods. A siRNA sequence that corresponds to the connective tissue growth factor (CTGF) 
was chosen as the model siRNA for its potential of breast cancer treatment. The TAT derived 
cell penetrating peptide Arginine-9 (R9) was chosen as the model peptide. In this study, we 
have utilized UV-Vis spectroscopy, circular dichroism, dynamic light scattering, Zeta 
potential measurements to investigate the physicochemical properties of CTGF siRNA-R9 
complexes, including their equilibrium binding ratio, complex structure, size, and surface 
charge. The driving force for the complexation reaction was also verified by a salt addition 
experiment. 
 
3.1 Materials and Methods 
 
siRNA and R9 Peptide. The connective tissue growth factor (CTGF) siRNA was chosen as 
the model siRNA for this study. It had a sense sequence of 
5’CGGUGUACCGAGCCCAGAUdTdT 3’ and an antisense sequence of 
5’AUCUCCGCUCGGUACACCGdTdT 3’. It was purchased from Dharmacon (processing 
option A4; Lafayette, CO). The molar concentrations of siRNA, were determined by 
absorption spectroscopy, using an extinction coefficient of 355021 L/mol•cm. Crude R9 
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peptide with N-terminal acetylation and C-termination amidation (AcN-RRRRRRRRR-
CNH2) was purchased from the Sheldon Biotechnology Center at McGill University 
(Montreal, QC). Peptide identity was confirmed by mass spectroscopy and HPLC. Other 
reagents were all commercially available and were of analytical grade. 
 
Preparation of siRNA-R9 complexes. Prior to use, siRNA and R9 peptides were first 
dissolved in Milli-Q water separately (Millipore, USA), divided in aliquots in 
microcentrifuge tubes, and stored in -20 oC after drying in Eppendorf Vacufuge Concentrator 
5301. SiRNA at concentrations 1.5 μM, 3.0 μM, and 4.5 μM was first suspended in HEPES 
buffer (6 mM HEPES-NaOH, 20 mM NaCl, 0.2 mM MgCl2, pH 7.3), then added to the dried 
peptide vials to achieve a final peptide concentration ranging from 0-60 uL. The resulting 
complex solutions were stirred vigorously for 10 s with a vortex mixer and incubated for 3 
hours at room temperature. 
 
UV-Vis Absorbance. UV-Vis absorption spectra of each sample was obtained on a Hewlett-
Packard 8452A diode array spectrophotometer (California, USA) at wavelengths between 
190 nm and 364 nm, using a 75 μL quartz cuvette. Background absorbances were subtracted 
from the acquired signal.  
 
Circular Dichroism. Circular dichroism (CD) measurements were preformed with a J-810 
Spectropolarimeter (Jasco, USA). Spectra were acquired from samples in a 55 μL, 3mm path 
length quartz cuvette at 25 oC. Spectra were scanned from 400 to 200 nm at 200 nm/min, 




Hydrodynamic Diameter and Zeta Potential Measurements. The hydrodynamic diameter of 
siRNA-R9 complexes was measured by dynamic light scattering (DLS) and Zeta potential by 
laser doppler velocimetry (LDV) at 25 ºC using a Zetasizer Nano ZS (Malvern, UK) 
equipped with a 4 mW He-Ne laser operating at 633 nm. All measurements were performed 
at 25 ºC at a measurement angle of 173º. SiRNA and R9 stock solutions were separately 
filtered through 0.2 μm non-protein binding syringe filters (Pall, USA) prior to complexation. 
The size and Zeta potential are presented as the mean value ± standard deviation from three 
measurements of at least 10 runs per measurement. 
 
Atomic Force Microscopy (AFM). A Picoscan atomic force microscope (Molecular Imaging, 
Arizona, USA) was used to study the morphology of the siRNA-R9 complexes/aggregates in 
solution. It was operated in Acoustic AC mode in solution using silicon nitride cantilevers 
(DNP-S, Digital Instruments), with a spring constant of 0.58 N/m and a typical tip radius of 
10 nm.  Tapping frequency is controlled in the range of 16-18 kHz.  400 μL of sample 
solution was deposited on a freshly cleaved mica surface.  To avoid evaporation, Teflon 
sealed liquid environmental chamber was used. 
 
Salt effect on siRNA-R9 binding. High concentration of salt can destabilize non-covalent 
interactions, including electrostatic interactions and hydrogen bonds. Two solutions were 
first prepared, one with 1.5 μM siRNA only and the other with an addition of 150 μM of R9. 
One hour after peptide addition, 2 M sodium chloride was separately added to the two 
 
33 
solutions. UV-Vis absorbance spectra of the two solutions were monitored before salt 





The interaction between CTGF siRNA and a cell penetrating peptide R9 has been 
investigated with various spectroscopic methods. The UV-Vis absorbance spectra of 3.0 μM 
siRNA in the absence and presence of R9 at concentrations ranging from 0 – 40 μM are 
shown in Figure 3-1. The characteristic peaks of siRNA at 210 nm and 260 nm are due to the 
presence of phosphate groups and nucleotide base pairs, respectively [177]. The addition of 
R9 induced a decrease in the absorbance of the complex solution. The hypochromic effect on 
siRNA absorbance due to peptide addition is more pronounced with increasing peptide 
concentration, until reaching saturation at peptide concentrations above 32 μM. 
Hypochromicity of siRNA spectra was also observed upon peptide addition at siRNA 
concentrations of 1.5 μM and 4.5 μM. It is also noted that the red/blue shift at absorption 




































Figure 3-1. Absorption spectra of siRNA in pH 7.3 HEPES buffer with increasing peptide 
concentration (from 0 to 40 μM). (From top to bottom) 
 
The hypochromic effect on siRNA due to the addition of R9 at a given wavelength can be 
quantified by the relative change in absorbance, ΔODr, defined as ΔODr=(ODo-OD)/ODo 
where ODo is the initial absorbance of the free siRNA and OD is the observed absorbance of 
the sample containing siRNA-peptide complexes. The hypochromic effect at 260 nm upon 
peptide addition, expressed in terms of peptide concentration, is quantified for siRNA 
concentrations of 1.5 μM, 3.0 μM, and 4.5 μM. (Figure 3-2) A plot of hypochromicity can 
also be presented with respect to charge ratio, which is a normalization of R9 concentration 
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with respect to siRNA concentration, expressed in terms of the charge ratio of positively 
charged R9 to negatively charged siRNA. (Figure 3-3)  
 
At 3.0 μM siRNA, the relative change in absorbance initially increases (UV absorbance at 
260 nm initially decreases) with increasing peptide concentration and eventually reaches a 
plateau after reaching saturation at 32 μM of R9, where only 7.8% of initial absorbance 
remained upon saturation. When hypochromicity was plotted against +/- charge ratio for 
siRNA concentrations of 1.5 μM, 3.0 μM, and 4.5 μM, a significant portion of the curves 
overlapped. The relative change in absorbance reaches its maximum at a charge ratio (+/-) of 
2.2, which corresponds to a molecular binding ratio of 10.3 peptides per siRNA.  
 
 
Figure 3-2. Hypochromicity of siRNA at 260 nm as a function of R9 concentration for 
siRNA concentrations of 1.5 μM (○), 3.0 μM (■), and 4.5 μM ( ). Solid lines are the line of 
















best fit generated by Prism.  Error bars represent the largest standard deviation from 3 
replicates at each siRNA concentration. 
 















Figure 3-3. Hypochromicity of siRNA at 260 nm as a function of +/- charge ratio for siRNA 
concentrations of 1.5 μM (○), 3.0 μM (■), and 4.5 μM ( ). Solid lines are the line of best fit 
generated by Prism.   
 
An important parameter for the determination of the optical properties of nucleic acids is the 
electric dipole transition moment (μOA), which represents the movement of charge density 
during the transition from the ground state to the excited state [177]. A larger dipole moment 
would result in a higher absorption band. In addition to contribution of absorbance from 
individual nucleic acid bases, interaction between nucleic acid bases or other species in 
solution also affect their absorption intensities. When the resultant transition dipole moment 
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is decreased, a decrease in absorbance occurs, and it is described as hypochromic. On the 
other hand, when the resultant transition dipole moment is increased, an increase in 
absorbance occurs and it is described as hyperchromic. When the guanidino groups from R9 
interact with nucleoside bases via hydrogen bonding, electron density contributed by the 
nucleic acid bases will be delocalized which resulted in a decrease in the magnitude of the 
electric dipole transition moment, and thus hypochromicity in the UV-Vis spectra.  
 
The analysis method developed by Bujalowski and Lohman [178] was applied to the 
absorbance data at 260 nm in attempt to obtain the equilibrium binding parameters between 
CTGF siRNA and R9 (see Supplementary information). However, the analysis method was 
found not to be applicable to this experimental system. The signal contributed by the siRNA 
at 260 nm is solely from the nucleoside bases and it is possible that the decrease in 
absorbance cannot reflect the interactions that underwent other modes of interaction, such as 
electrostatic interaction with the phosphate backbone. More likely, aggregation of 
complexes, which was not included in the derivation developed by Bujalowski and Lohman, 




The circular dichroic (CD) spectra of siRNA-R9 complexes prepared at various R9 
concentrations at 3.0 mM siRNA are shown in Figure 3-4. The siRNA has characteristic 
peaks around 210 nm and 265 nm (see Supplementary Information), which, when compared 
to the CD spectrum of established nucleic structures [177], confirms that the siRNA 
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possesses a right handed structure, similar to that of A-DNA. As the concentration of R9 
increases, the ellipticity of complex solutions decreases progressively, until reaches a plateau 
at R9 concentrations above 35 μM.  
 
Similarly, the relative change in ellipticity, Δθr, is defined as Δθr=(θo-θ)/θo, where θo is the 
initial ellipticity of the free siRNA and θ is the observed ellipticity of the sample containing 
siRNA-peptide complexes. A plot of the relative change in ellipticity over increasing R9 
concentration, expressed separately in terms of R9 concentration and +/- charge ratio, is 
given in Figure 3-5 and Figure 3-6 respectively. By monitoring the changes in the CD spectra 
upon titration of peptide, the stoichiometry was found to be 10.7 R9 peptides per siRNA at 
saturation (+/- charge ratio of 2.2), which agrees with the results given by UV absorbance. 
Previous study on the binding between poly-L-arg and nucleotides [180] has obtained a 
binding ratio of 2 arginine to one nucleotide, which corresponds to binding ratios between 




























Figure 3-4. Circular dichroic spectra of siRNA in pH 7.3 HEPES buffer with increasing 






























Figure 3-5. Relative change in ellipticity of siRNA at 260 nm as a function of R9 
concentration for siRNA concentrations of 1.5 μM (○) and 3.0 μM (■). Solid lines are the 





























Figure 3-6. Relative change in ellipticity of siRNA at 260 nm as a function of +/- charge 
ratio for siRNA concentrations of 1.5 μM (○) and 3.0 μM (■). Solid lines are the line of best 
fit generated by Prism.   
 
Circular dichroism measures the difference in absorption spectrum between left-handed and 
right handed polarized light. Therefore, CD provides sensitive and unique spectra for chiral 
molecules, and it has been widely used in structural determination of proteins and nucleic 
acids. With increasing R9 concentrations, the ellipticity of complex solution decreased, while 
the maximum and minimum peaks experience negligible shifting, which suggested that the 
structure of the siRNA experienced minimal structural changes upon interacting with R9. 
The decrease in ellipticity of siRNA due to increasing peptide concentration can be attributed 
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to the decrease in absorbance of the nucleosides in siRNA-R9 complexes, similar to the 
spectra obtained by UV-Vis spectroscopy.  
 
Hydrodynamic Diameter and Zeta Potential Measurements 
 
The size and surface charge of the siRNA-R9 complexes are characterized by measuring the 
hydrodynamic diameter and Zeta potential (Figure 3-7). CTGF siRNA adopts the structure of 
the right-handed A form of DNA in solution, with a measured hydrodynamic diameter of 
5.21 nm, which is very close to the theoretical value of 5.46 nm for a 21 base pair siRNA 
[181]. R9 peptide adopts a random coil structure (also confirmed by CD), and its 
hydrodynamic diameter is found to be 6.81 nm. With increasing peptide concentration, both 
the hydrodynamic diameter and Zeta potential of the complex solution increased. The size of 
the complexes increases until its value reaches 1055.8 nm. The Zeta potential of CTGF 
siRNA in HEPES is -36.2 mV, which reflects the contribution from the 42 negative charges 
on the phosphate group at neutral pH; whereas the Zeta potential of R9 in HEPES is 28.1 
mV, due to the positively charged guanidino group. The increase in Zeta potential is the most 
pronounced when the charge ratio is between 1.43 and 8.57 mV, while its value increased 


























































Figure 3-7. Hydrodynamic diameter and Zeta potential of CTGF siRNA-R9 complexes at 
1.5 μM siRNA. Zeta potential of siRNA and siRNA-R9 complexes is expressed in solid bars; 
Zeta potential of R9 is represented by diagonal bar; and size is represented by a solid line. 
 
The rate of increase in the hydrodynamic diameter is at maximum when the charge ratio is 
between 1.43 and 8.57, where the value of the surface charge is low. The increase in 
hydrodynamic diameter strongly demonstrated that the two species interact with each other. 
Further, since the hydrodynamic diameter increased by almost 200 fold, the results also 




According to the DVLO theory for colloidal systems [182], the energy barrier resulting from 
the repulsive force prevents two particles approaching one another and adhering together. 
However, when sufficient energy is given to overcome the barrier, the attractive forces will 
pull them into contact where they adhere strongly and/or irreversibly together. When the 
complexes have low Zeta potential, electrostatic repulsion is low thus the particles in solution 
can adhere to each other and result in large aggregates. The results from DLS and Zeta 
potential suggest that the complexation reaction is saturated when the charge ratio is above 
8.57, which is higher than the values obtained by UV-Vis spectroscopy and CD. Thus, it is 
suggested that the hydrogen bonding sites between nucleosides and R9 is first depleted 
among the three. It can be seen that UV-Vis spectroscopy and CD can detect the 
complexation of siRNA and R9 only at charge ratio below 2.2.:1, further complexation and 
aggregation phenomena cannot be detected by these two methods. Furthermore, it is worth 
noting that UV-Vis absorbance and CD signal has reached saturation at a charge ratio of 
~2.2:1, which is very close to the isoelectric point of the siRNA-R9 complexes.   
 
Moreover, since size and surface charge are the essential parameters contributing to the 
activation of the complement system. As seen in Figure 3-7, peptide concentration can be 
used to control the size and surface charge of the siRNA-R9 complexes so that the interaction 






Morphology of siRNA-R9 complexes 
 
Atomic force microscopy has been used to determine the morphology of the siRNA-R9 
complexes. As seen in Figure 3-8, the siRNA-R9 complexes are shown to have a poly-
dispersed, globular structures on mica surfaces. Furthermore, these small globular structures 
tend to aggregate to form larger structures.   
 
 
Figure 3-8 In solution atomic force microscopy image of CTGF siRNA (3.0 μM) and R9 (35 







Salt effect on siRNA-R9 binding 
 
Ionic interaction contributed by salts can destabilize non-covalent interactions. In this study, 
a high concentration of sodium chloride (2 M) was added to the siRNA-R9 complex solution 
to investigate the driving force of the complexation reaction. Similar to the UV-Vis 
abosorbance results above, hypochromicity is seen when excess peptide is added to siRNA, 
where the absorbance dropped by 83.0% in one hour following peptide addition (Figure 3-9). 
Two hours after the addition of 2 M sodium chloride, the absorbance of the complex solution 
increased and its absorbance is 13.1% lower than the absorbance of siRNA under the same 
treatment. The absorbance of the complex solution was monitored after one day and the 


























Figure 3-9. Absorbance at 260 nm of siRNA (1.5 μM) and siRNA-R9 (1.5 μM / 150 μM) 
complex solution upon 2 M salt addition. The absorbance of siRNA only and siRNA-R9 
complex solutions are monitored prior to salt addition (white), 2 hours after salt addition 
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Design of Peptide Carriers and Preliminary in vitro Evaluation 
Despite the versatility and biodegradability of the peptide delivery system, its use for nucleic 
acid delivery is limited by its low transfection efficiency when compared to lipid and virus 
based delivery systems. Since peptide carriers has promising potential in transfecting siRNA 
efficiently, it is the interest of our group to develop new peptide sequences that can promote 
siRNA transfection efficiency. 
 
The desired properties of the new peptide carrier include:  
• The peptide should interact with siRNA through non-covalent interactions such as 
Columbic forces and hydrogen bonding. In particular, basic amino acids such as lysine 
and arginine can interact with the negatively charged phosphate group on the sugar ring 
through electrostatic interaction.  Covalent bonds between the carrier and siRNA such as 
conjugation, and the use of cross-linking agents, increase the complexity of the design 
and processing of the siRNA formulation.  
• The carrier should have high siRNA loading capacity so that more siRNA can be 
delivered at low cost. 
• The optimal size for cellular internalization through endocytosis is between 100 nm to 
200 nm in diameter, whereas smaller complexes, depending on their surface properties, 
can directly penetrate the cell membrane. Cellular translocation of larger complexes 
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experiences increasing difficulties. Since endocytosis is one of the most common routes 
for cellular translocation, the siRNA-peptide complexes should be controlled to have a 
size below 200 nm.  
• Surface charge of the siRNA-peptide complexes is an essential parameter towards 
complex aggregation and the triggering of immune response through complement 
activation.  Therefore, the surface charge of siRNA-peptide complexes should be 
controlled within a narrow range so that the complexes are free from aggregation and are 
stealth from the immune system. 
• Various exonucleases are able to degrade siRNA prior silencing of protein expression. 
Therefore one of the most important properties of siRNA-carrier complexes is to protect 
the siRNA from premature degradation and other harsh environments.   
• Previously published sequences were analyzed and amino acids with specific functions 
were identified to be incorporated in new sequences. These amino acids include pH 
sensitive amino acids histidine and glutamic acid, as well as basic amino acids lysine and 
arginine. 
• It is very important that the peptide carrier is biocompatible.  Therefore, cytotoxicity 








4.1 New Peptide Sequences 
 
Based on the above design criteria, 54 peptides (including controls) in 5 categories were 
designed:   
 
The first group contains eight peptides that mainly consist of arginine and histidine. Two 
previous studies [155,183] have investigated the translocation efficiency of arginine peptides 
of various lengths. It is found that arginine peptides with seven to nine residues have the 
highest translocation efficiency, while at least five arginine residues are required for 
translocation to take place. Histidine is a pH sensitive amino acid as it will be protonated at 
low pH.  When histidine containing peptide is taken in the endosome during endocytosis, it 
acts as a proton sponge which disrupts the endosomal pH; this results leakage of the 
endosomal content, which release the siRNA complexes to the cytosol. The two amino acids 
are utilized in this design to combine the cell penetration property and the endosome 
disruptive property. The chain length effect of each residue as well as the effect of charge 
distribution is investigated among this group of peptides. 
 
The second group consists of peptides that are designed to have an α-helical secondary 
structure that have three distinct sections when viewed from the top, each contributed by the 
amino acids leucine, histidine and arginine. It is believed that hydrophobic residues such as 
leucine can assist in cell penetration through interacting with the hydrophobic tails in the 
lipid bilayer (ref), and also assist in pore formation in the cell membrane. A three factor 
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center composite design was incorporated in the primary sequences, for the investigation of 
the effect of peptide chain length, hydrophobicity, and face angle in the helical structure. The 
secondary structure of the designed peptides was predicted using NNPREDICT [184].   
 
Since many peptide delivery carriers are designed based on α-helix amphiphilicity 
[97,108,170] while investigations based on amphiphilic β-sheet peptides are very limited 
[108,171]. Therefore, the third group consists of peptides was designed to investigate the 
possibility of using peptides with β-strand secondary structures as delivery vehicle.  This 
group of peptide consists of ionic complementary peptides, which can self-assemble through 
complementarily of ionic residues and hydrophobic forces, and also peptides that are 
designed to be ionic complementary as well as having geometric matches between basic 
amino acid residues and phosphate backbone.   
 
Wender et al. have shown that oligo-D-arginine has higher cell penetrating efficiency when 
compared to the natural occurring oligo-L-arginine [101]. This group of peptides has natural 
occurring L-arginine substituted with D-arginine.  
 
The final group of peptide contains the derivatives of known peptide sequences, including 
various cell penetrating peptides, endosomal disruptive peptides, and self-assembly peptides. 
For example, amino acids lysine and alanine are substituted with arginine and leucine for 




These newly designed peptides are expected to enhance the transfection efficiency of siRNA 
upon complexation. The transfection efficiency of the siRNA-peptide complexes was 
monitored by the green fluorescence emitted by a green fluorescence protein (GFP) 
containing cell line C166-GFP through fluorescence microscopy and fluorescence detected 
flow cytometry. However, due to time constraints, the transfection efficiency was evaluated 
on peptides listed in Table 4-1 only. 
 




pH 4.2 Name # of a.a. Sequence 






+ - + - 
R9 9 n-RRRRRRRRR-c ---------  0 0.0000 9 0 9 0
EAK 
16 IV 16 
n-AEAEAEAEAKAKAKAK-c --HHHHHHHHHHHH-- 12 0.3945 4 4 4 2
EAK 
16 II 16 
n-AEAEAKAKAEAEAKAK-c --HHHHHHHHHHHH-- 12 0.3945 4 4 4 2
ACS 11 n-ACSSSPSKHCG-c -----------  0 0.4445 1 0 2 0
ACS-
R9 23 
n-ACSSSPSKHCGGGGRRRRRRRRR-c ----------------------- 0 0.2720 10 0 11 0
 
 
4.2 Materials and Methods 
 
Cell Culture. Mouse endothelial cells C166-GFP was purchased from American Type Cell 
Culture (ATCC CRL-2583; VA, USA).  The cell line was transfected with pEGFP-N1 
(Clontech, CA, USA) that encodes the enhanced green fluorescence protein (eGFP) by the 
depositor.  C166-GFP cells were maintained in low glucose Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen, ON, Canada), supplemented with 10% heat inactivated fetal 
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bovine serum (FBS; Invitrogen, ON, Canada) and 0.02mg/mL G418 (Sigma Aldrich, 
Canada).  
 
SiRNA, Peptides, and Transfection Agent. The eGFP siRNA with target sequence 5'-GCG 
ACG TAA ACG GCC ACA AGT TC -3' was purchased from Dharmacon (Cat. No. P-
002102-01-20; CO, USA). The molar concentrations of siRNA, were determined by 
absorption spectroscopy, using an extinction coefficient of 362,408 L/mol•cm. A peptide 
array consists of crude peptide swith N-terminal acetylation and C-termination amidation 
was purchased from Pepscan Systems (Leystad, Netherlands). Peptide identity was 
confirmed by mass spectroscopy. Other reagents were all commercially available and were of 
analytical grade. The transfection agent Lipofectamine 2000 (Invitrogen, ON, Canada) was 
used as a positive control for comparison. The dosage of Lipofectamine 2000 was controlled 
at a siRNA ratio of 20 pmol to 1 μL, as suggested by the manufacturer. 
 
Preparation of siRNA-peptide complexes. Prior to use, siRNA was first dissolved in Milli-Q 
water (Millipore, USA), divided in aliquots in microcentrifuge tubes, and stored in -86 oC 
after drying in Eppendorf Vacufuge Concentrator 5301. Stock siRNA was prepared in 
HEPES buffer (6 mM HEPES-NaOH, 20 mM NaCl, 0.2 mM MgCl2, pH 7.3). Peptides were 
first dissolved in dimethyl sulfoxide (DMSO) one day prior to transfection. Stock siRNA and 
peptide solutions were then balanced with HEPES to obtain desired concentrations for 
complexation (10X final concentration at 50 μL per sample). The maximum siRNA 
concentration used was 160 nM and the highest peptide concentration used was at a +/- 
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charge ratio of 20:1. The resulting complex solutions were stirred vigorously for 10 s with a 
vortex mixer and incubated for 3 hours at room temperature. 
 
Transfection Protocol. C166-GFP cells were seeded at 15000 cells/well on 24 well plates one 
day before transfection.  Fifty microlitres of complex solution and 200 μL of DMEM were 
added to each well. After four hours, 250 μL of DMEM with 20% FBS was added to each 
well.  Cells were harvested over two days for eGFP fluorescence monitoring.  
 
Fluorescence Microscopy. The eGFP from the siRNA transfected cells were observed using 
an Axiovert 200 Fluorescence Microscope (Carl Zeiss, Jena, Germany) equipped with a 10x 
objective, directly on 24-well plates, without cell fixation. The excitation and emission filters 
for fluorescence imaging have band passes of 485±20 nm and 525±25 nm, respectively.  
 
Cell Fixation. Upon siRNA transfection, C166-GFP cells were harvested over 2 days, fixed 
in 2% paraformaldehyde (PFA) for the detection of eGFP expression by flow cytometry.  
Each well on the 24-well plate was first rinsed with 500 μL phosphate buffered saline (PBS) 
once, trypsinized with 200 μL of 0.25% trypsin-EDTA, and the cells were resuspended by 
Mg2+ and Ca2+ containing PBS. The cells were centrifuged at 1000 rpm for 10 mins, and then 
the supernantant was removed. The cells were then resuspended in 2% PFA and stored at 4 
oC until flow cytometry analysis.   
 
Flow Cytometry. Fluorescence and light scattering intensity distributions of C166-GFP cells 
were obtained by flow cytometry (FACS Vantage SE, Becton Dickinson, USA) with a laser 
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excitation wavelength of 488 nm. Fluorescence emission of eGFP is obtained with a 530 ± 30 
nm band pass filter. At least 5000 events were recorded. Data were analyzed by FCS Express 
software (Version 3). Gates were applied to exclude cell debris and unhealthy cells from 
analysis. 
 
4.3 Results and Discussion 
 
In this study, C166-GFP cells were transfected with eGFP siRNA, using peptides as a 
delivery carrier. The efficiency of siRNA silencing is monitored at the protein level where 
the eGFP fluorescence was monitored by fluorescence microscopy and flow cytometry. For 
effective eGFP silencing, the eGFP fluorescence intensity is expected to decrease upon 
siRNA transfection since the mRNA encoding for the eGFP is degraded. Upon reaching the 
cytosol, the successfully delivered siRNA would perform RNAi which prevents the 
downstream production of eGFP until the siRNA is eventually degraded by endonucleases. 
However, GFP that is already present in the cytosol prior to siRNA delivery would still give 
fluorescence before it is degraded by intracellular proteases. Therefore, it is very important to 
monitor the effect of silencing over time. The effect of siRNA silencing was monitored over 
2 days at 24 hours and 48 hours. The base line of eGFP fluorescence is obtained from the 
fluorescence of untreated cells. The normal and positive controls were cells transfected with 
naked siRNA and siRNA-Lipofectamine 2000 complexes, respectively. Due to time 
constraints, only five peptides, R9, EAK 16 IV, ACS, ACS-R9, and EAK 16 II were 
investigated. (Table 4-1) 
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4.3.1 Optimization of siRNA Dosage by Fluorescence Microscopy 
 
The dosage for siRNA transfection has to be controlled within a very specific range. The 
extent of siRNA silencing is limited when a low dosage is used; however, sequence non-
specific silencing can be triggered when the siRNA dosage is too high [185]. In general, the 
siRNA dosage used for transfection is at a maximum of 100 nM [186]. Detectable 
transfections with siRNA concentration as low as 25 nM  have been reported [187,188]. 
Optimization of siRNA dosage was performed with siRNA concentrations ranging from 0 to 
160 nM, using Lipofectamine 2000 as transfection agent. The effect of eGFP silencing was 
monitored using Fluorescence microscopy. (Figure 4-1)  
 
The brightness of GFP from the fluorescence images was used as an indicator of the siRNA 
silencing efficiency. As seen in Figure 4-1, when the dosage of siRNA increases, the 
brightness of the GFP in the fluorescence images decreases. Silencing effect of eGFP has 
become significant when siRNA concentration reaches 80 nM. Furthermore, at siRNA 
concentration of 120 and 160 nM, a decrease in confluency is observed, which indicates a 
decrease in cell viability. Cytotoxicty is also observed in the Lipofactamine 2000 only 
control (dosage used is equivalent to the volume required to tranafect siRNA at 100 nM). The 
decrease in cell viability is mainly due to the non-specific silencing effect happened at high 
siRNA concentration, or due to the increased cytotoxicity of the liposome based transfection 
agent [77,79,84]. From the siRNA dosage optimization results, it is found that 80 nM siRNA 
is able to provide a significant silencing effect while maintaining high cell viability. The 
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Figure 4-1. C166-GFP cells at 48 hours after eGFP siRNA transfection, using Lipofectamine 




4.3.2 Transfection Efficiencies of Peptides Candidates 
 
Five peptides from Table 4-1, R9, EAK 16 IV, ACS, ACS-R9, and EAK 16 II were used as 
carriers in siRNA transfection.  The fluorescence intensities of transfected cells were 
monitored after 24 hours and 48 hours, using fluorescence microscopy (Figures 4-2 to 4-11) 
and fluorescence detected flow cytometry (Figures 4-12 to 4-19).  
 
Both bight field images and fluorescence images of the C166-GFP cells treated with siRNA-
peptide complexes at various charge ratios, together with the negative controls, are shown in 
Figure 4-2 to 4-11, where Figure 4-2 to 4-6 are the images taken at 24 hours whereas Figure 
4-7 to 4-11 are the images taken at 48 hours. By comparing the GFP intensities between the 
non-treated cells and the siRNA-peptide complex treated cells at 24 and 48 hours, it can be 
seen that there is no significant decrease in fluorescence intensity from the siRNA-peptide 
complexes treated cells when compared to the siRNA-Lipofectamine 2000 treated cells 













































Figure 4-2. C166-GFP cells at 24 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using R9 as transfection agent. Fluorescence and the corresponding bright field 
images are shown. Fluorescence images of the peptide controls are shown in the Appendix. 
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Figure 4-3. C166-GFP cells at 24 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using EAK 16 II as transfection agent. Bottom panel shows the peptide only 
controls for the corresponding peptide concentration used for siRNA transfection in the top 
panel. Fluorescence and the corresponding bright field images are shown. 
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Figure 4-4. C166-GFP cells at 24 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using EAK 16 IV as transfection agent. Fluorescence and the corresponding 


































Figure 4-5. C166-GFP cells at 24 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using ACS as transfection agent. Bottom panel shows the peptide only controls 
for the corresponding peptide concentration used for siRNA transfection in the top panel. 
Fluorescence and the corresponding bright field images are shown. 
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Figure 4-6. C166-GFP cells at 24 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using ACS-R9 as transfection agent. Bottom panel shows the peptide only 
controls for the corresponding peptide concentration used for siRNA transfection in the top 
panel. Fluorescence and the corresponding bright field images are shown. 
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Figure 4-7. C166-GFP cells at 48 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using R9 as transfection agent. Fluorescence and the corresponding bright field 
images are shown. Fluorescence images of the peptide controls are shown in the Appendix. 
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Figure 4-8. C166-GFP cells at 48 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using EAK 16 II as transfection agent. Fluorescence and the corresponding 
bright field images are shown. 
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Figure 4-9. C166-GFP cells at 48 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using EAK 16 IV as transfection agent. Fluorescence and the corresponding 






































Figure 4-10. C166-GFP cells at 48 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using ACS as transfection agent. Fluorescence and the corresponding bright 
field images are shown. 
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Figure 4-11. C166-GFP cells at 48 hours after eGFP siRNA transfection at specified +/- 
charge ratios, using ACS-R9 as transfection agent. Fluorescence and the corresponding 
bright field images are shown. 
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The GFP intensities of the C166-GFP cells treated with siRNA-peptide complexes at various 
charge ratios are shown in Figure 4-13 to 4-22, where Figure 4-13 to 4-17 are the images 
taken at 24 hours whereas Figure 4-18 to 4-22 are the images taken at 48 hours. The 
negative, positive, and neutral controls are shown in Figure 4-12. The positive control of 
using Lipofectamine 2000 as siRNA transfection agent significantly decreased the GFP 
intensity of C166-GFP cells. However, by comparing the GFP intensities between the non-
treated cells and the siRNA-peptide complex treated cells at 24 and 48 hours, it can be seen 
that there is no significant decrease in fluorescence intensity from the siRNA-peptide 


































Figure 4-12. FACS results for the negative, positive, and normal controls (from left to right), 
which corresponds to non-treated cells, siRNA-Lipofactamine 2000 treated cells, and naked 




Figure 4-13.  FACS results for siRNA-R9 transfected cells in 24 hours at charge ratio (+/-) 
of 2:1, 5:1, and 10:1 (from left to right). 
 
  
Figure 4-14.  FACS results for siRNA-EAK 16 II transfected cells in 24 hours at charge ratio 
(+/-) of 2:1, 5:1, and 10:1 (from left to right). 
 
 
Figure 4-15.  FACS results for siRNA-EAK 16 IV transfected cells in 24 hours at charge 
































































Figure 4-16.  FACS results for siRNA-ACS transfected cells in 24 hours at charge ratio (+/-) 

































Figure 4-17.  FACS results for siRNA-ACS-R9 transfected cells in 24 hours at charge ratio 

































Figure 4-18.  FACS results for siRNA-R9 transfected cells in 48 hours at charge ratio (+/-) 


































Figure 4-19.  FACS results for siRNA-EAK 16 II transfected cells in 48 hours at charge ratio 

































Figure 4-20.  FACS results for siRNA-EAK 16 IV transfected cells in 48 hours at charge 

































Figure 4-21.  FACS results for siRNA-ACS transfected cells in 48 hours at charge ratio (+/-) 



































Figure 4-22.  FACS results for siRNA-ACS-R9 transfected cells in 48 hours at charge ratio 
(+/-) of 2:1, 5:1, and 10:1 (from left to right).  
 
This shows that at the concentration of peptide carrier used, the peptide candidates failed to 
promote the efficiency of siRNA transfection. The inefficient siRNA transfection is possibly 
due to the dissociation of siRNA-peptide complexes in the cell culture medium, or the 
siRNA-peptide complexes cannot be taken into the cytosol. Therefore, these peptides are 
deemed inefficient in promoting the efficiency of siRNA transfection within the range of 
experimental conditions. C166-GFP cells remained to be highly viable since their 
morphology observed from the scatter plots remained similar to the untreated cells (see 
Appendix) and they appeared to be healthy when observed under the microscope. Therefore, 
both the siRNA-peptide complexes and the peptide carrier are not cytotoxic within 
experimental conditions. In future studies, higher peptide concentrations should be used in 
order to verify the siRNA transfection efficiency of these peptide candidates. Unlike 
Lipofectamine 2000, cell viability is maintained in all cases, which indicates cytotoxicity due 






Arginine-9 and connective tissue growth factor siRNA has been used as a model for the 
physicochemical characterization of siRNA-peptide complexes. Further, new peptide 
candidates for siRNA transfection were designed. Preliminary in vitro investigation of 
peptides mediated cellular delivery of siRNA was investigated using fluorescence 
microscopy and flow cytometry on selected peptide sequences. The following conclusions 
can be drawn from the above experiments:  
• The highest binding ratio for siRNA-R9 complexes was determined to be 10.3 R9 to 
one siRNA (corresponds to 2.2 in +/- charge ratio).  
• From the CD spectra, it is suggested that the confirmation of siRNA did not undergo 
significant changes.  
• SiRNA and R9 interact non-covalently and readily form aggregates through self 
association, with a maximum hydrodynamic diameter of ~1μm at siRNA saturation. 
Aggregation is due to the decrease in surface charge at increasing peptide 
concentration as demonstrated by Zeta potential measurements.  
• The difference in binding ratio (UV/Vis spectra and CD is 10.3:1 and 39.1:1 from 
DLS) is possibly due to the difference in signal contribution between absorption and 
light scattering. Since the signal from absorption measurements is solely contributed 
by the nucleoside bases, it cannot represent the extent of the overall reaction.  
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• The optimal siRNA concentration for transfection is found to be 80 nM using 
Lipofectamine 2000. 
• Selected peptide sequences, including R9, EAK 16 II, EAK 16 IV, ASC, and ASC-
R9, when non-covalently bonded to eGFP siRNA, did not significantly enhance the 





Future Work and Recommendations 
In order to gain further insight in the physicochemical properties of siRNA-peptide 
complexes and investigate their effect on siRNA silencing, future research in this area can 
focus on the following:  
• Complete the screening of peptide library.  Since the methodology of peptide 
screening is developed, it should be extended to exploit the siRNA delivery capability 
of the remainders of the peptide library. 
• A complement method of siRNA silencing detection at the protein level should be 
used. The focus of this research is to monitor the silencing efficiency through eGFP 
expression; however, complementary methods such as monitoring luciferase intensity 
and the concentration of a specific protein could be used as well. 
• The effect of siRNA silencing should be extended to monitor at the mRNA level. 
Methods such as RT-PCR can be used to determine the change in mRNA 
concentration in various siRNA treated samples. 
• Once a promising peptide candidate is identified from the library using in vitro 
methods, further experiments should be done to characterize its properties.  In 
particular, the experiments should be directed to investigate the physicochemical 
properties of the siRNA-peptide complexes, as well as cytotoxicity studies using 
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Equilibrium Binding Isotherm Determination 
 
SiRNA has 42 negative charges per molecule and R9 has 9 positive charges per molecule.  
Therefore, it is expected that siRNA molecules can interact with multiple R9 molecules 
through columbic forces. (Figure A1a)  Furthermore, two hydrogen atoms from the 
guanidino group of each arginine can hydrogen bond with the oxygen and nitrogen at the 
purine base of guanine within the major groove of the GC base pair. (Figure A1b)  It is 
anticipated that electrostatic interaction and hydrogen bonding are the major driving forces 
for the interaction between siRNA and R9.  (This is verified by salt dissociation experiment.)  
In other words, siRNA is present as a macromolecule that can interact with multiple R9 
ligands in a non-sequence-specific and non-covalent manner.  In order to characterize the 
complexation reaction quantitatively, it is essential to obtain an accurate equilibrium binding 







Figure A1 (a) Columbic interactions between positively charged guanidino group of arginine 
and negatively charged phosphated group of siRNA. (b) Hydrogen bonds between guanidino 
group of arginine and guanine of siRNA in the major groove. [1] 
 
Hypochromic effect of siRNA absorbance at 260 nm is observed upon its interaction with 
R9.  By increasing peptide concentrations at a fixed siRNA concentration, three titration 
curves expressed in terms of hypochromicity were obtained at siRNA concentrations of 1.5 
uM, 3.0 uM, and 4.5 uM.   
 
According to thermodynamics, the interaction between siRNA and R9 would establish 
equilibrium between the free siRNA sites, free peptide and bound siRNA sites.  A siRNA 
molecule consists of 21 base pairs and it forms a double helical structure with two 3’ 
overhangs.  It can be viewed as a linear lattice with N repeating units.  It is assumed that each 
R9 covers the same number of phosphate groups (n) on a siRNA.  Since hypochromicity is 
observed upon R9-siRNA complexation, it follows that the extinction coefficients of the 




state i has a distinct extinction coefficient, then according to the Beer’s Law, the optical 









ll εε  (1) 
 
where respectively εf and Mf are the extinction coefficient and molar concentrations of 
phosphate groups of unbound siRNA, εbi and Mbi are extinction coefficient and molar 
concentrations of phosphate groups of bound siRNA in state i, l is the light path length of 
cuvette.   
 
On the other hand, the mass conservation equation between Mf, Mb and Mt, which represents 
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Furthermore, the binding density of the siRNA at state i, νi, is defined as the number of 
















where, Lbi is the bound peptide concentration for complexes in stage i. 
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Given that the absorbance of the free siRNA, ODi is simply εflMt, the relative change in 
absorbance expressed in terms of hypochromicity (H), can be related to the extent of binding 
by 
 




ODODH εν  (5) 
 
where riεΔ  is the relative change in extinction coefficient at state i.  Therefore, the 
experimentally observed hyprochromicity is only a function of binding density νi.  Further, to 
show that the fraction of siRNA bound is only a function of the free peptide concentration Lf, 
consider the equilibrium between the free siRNA sites, free peptide and bound siRNA sites: 
 








where K represents the equilibrium binding constant, which is related to the equilibrium 











= /1  (6) 
 
where Mb is the sum siRNA phosphate concentrations for all binding states, and it is equal to 
ΣMbi. 
Substitute reaction site conservation equation (Equation 2) into Equation 6 and express in 




























From Equation 7, it is shown that the overall binding density is only a function of free 
peptide concentration. Equation 5 illustrated that the experimental observed hypochromicity 
is a unique function of the binding density, whereas Equation 7 demonstrated that the binding 
density is a unique function of the free peptide concentration. In other words, hypochromicity 
is also a unique function to the free peptide concentration, related through the binding 
density.  As a result, the free peptide concentration and binding density will be constant for a 
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When two siRNA titration curves were obtained, the binding density and free peptide 
concentration at each hypochromicity can be obtained with a set of two simultaneous 
equations of Equation 8.  When three or more siRNA titration curves were obtained, the 
above quantities can be obtained through linear regression of Equation 8.  Through the use of 
the above analysis technique by Lohman and Bujalowski [2], a model independent binding 
isotherm can be obtained without applying any assumptions. 
 
Fitted values of total peptide concentration are calculated at chosen hypochromicity values 
for siRNA concentrations of 1.5uM, 3.0uM, and 4.5uM.  Linear regression is performed 
according to Equation 8 to obtain binding densities and free peptide concentrations at each 
hypochromicity value.  However, the calculated free peptide concentration is negative in the 
experimental relevant range, which means that this analysis is not applicable to this 
experimental system. Figure A 2 is a plot of binding densities versus free peptide 
concentrations. Since the signal contributed by the siRNA is solely from the nucleoside bases 
and it is possible that the decrease in absorbance cannot reflect the interactions that undergo 
other modes of interaction, such as electrostatic interaction with the phosphate backbone and 
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charge dipole interaction with the sugar ring. Furthermore, aggregation of complexes also 
affects the applicability of this method. 




























Figure A 2. Calculated binding isotherm for CTGF siRNA-R9 complexes.  Following the 
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Figure A 3. AFM Images for the experimental controls: siRNA at 1000 nM (left), R9 at 100 uM 



















































Figure A 4. Controls for the C166-GFP transfection experiments, taken at 24 hours after 
eGFP siRNA transfection. Negative and positive controls are cells with no treatment and 
cells treated with Lipofectamine 2000-siRNA complexes, respectively. Normal controls 
include cells treated with naked siRNA, mock treatment, and peptide carrier only. 
Fluorescence and the corresponding bright field images are shown.  
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Figure A 5. Controls for the C166-GFP transfection experiments, taken at 48 hours after eGFP 
siRNA transfection. Negative and positive controls are cells with no treatment and cells 
treated with Lipofectamine 2000-siRNA complexes, respectively. Normal controls include 
cells treated with naked siRNA, mock treatment, and peptide carrier only. Fluorescence and 
the corresponding bright field images are shown. 
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Figure A 6. Controls for the C166-GFP transfection experiments, taken at 48 hours after eGFP 
siRNA transfection. Negative and positive controls are cells with no treatment and cells 
treated with Lipofectamine 2000-siRNA complexes, respectively. Normal controls include 





Figure A 7. FACS results for the negative (Top), positive (Middle), and normal (Bottom) controls 
shown in three plots: forward versus side scatter (left column), GFP intensity plots (middle column), 
and GFP fluorescence versus side scatter (right column). The gate applied for the analysis of result is 









































































































Figure A 8.  FACS results in terms of scatter plot (left), histogram of fluorescence (middle), and side 
scatter versus fluorescence intensity (right), for siRNA-R9 transfected cells in 24 hours at charge ratio 




Figure A 9.  FACS results for siRNA-EAK 16 IV transfected cells in 24 hours at charge ratio (+/-) of 







Figure A 10.  FACS results for siRNA-ACS-R9 transfected cells in 24 hours at charge ratio (+/-) of 














































































































Figure A 11.  FACS results for siRNA-ACS transfected cells in 24 hours at charge ratio (+/-) of 2:1 
















































































































Figure A 12.  FACS results for siRNA-EAK 16 II transfected cells in 24 hours at charge ratio (+/-) of 














































































































Figure A 13.  FACS results for siRNA-R9 transfected cells in 48 hours at charge ratio (+/-) of 2:1 











































































































Figure A 14.  FACS results for siRNA-EAK 16 IV transfected cells in 48 hours at charge ratio (+/-) 




















































































































































































































Figure A 15.  FACS results for siRNA-ACS-R9 transfected cells in 48 hours at charge ratio (+/-) of 










































































































Figure A 16.  FACS results for siRNA-ACS transfected cells in 48 hours at charge ratio (+/-) of 2:1 










































































































Figure A 17.  FACS results for siRNA-EAK 16 II transfected cells in 48 hours at charge ratio (+/-) of 





Figure A 18. FACS results for ACS-R9 only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 



















































































































Figure A 19. FACS results for EAK 16 II only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 


















































































































Figure A 20. FACS results for ACS only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 5:1 




















































































































































































































Figure A 21. FACS results for ACS-R9 only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 












































































































Figure A 22. FACS results for EAK 16 II only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 












































































































Figure A 23. FACS results for ACS only controls in 24 hours at charge ratio (+/-) of 2:1 (Top), 5:1 





Figure A 24.  FACS results for siRNA- R9 transfected cells in 24 hours at charge ratio (+/-) of 1:1 




Figure A 25.  FACS results for siRNA- EAK 16 IV transfected cells in 24 hours at charge ratio (+/-) 





Figure A 26. FACS results for the negative (Top) and  positive (Bottom) controls shown in three 
plots: forward versus side scatter (left column), GFP intensity plots (middle column), and GFP 
fluorescence versus side scatter (right column). The gate applied for the analysis of result is shown in 











































































Figure A 27.  FACS results for siRNA- R9 transfected cells in 48 hours at charge ratio (+/-) of 1:1 




Figure A 28.  FACS results for siRNA- EAK 16 IV transfected cells in 48 hours at charge ratio (+/-) 










































































































Figure A 29. FACS results for peptide only controls in 24 hours at charge ratio (+/-) of 20:1 for R9 
(Top) and EAK 16 IV (Bottom). 
 
Figure A 30. FACS results for peptide only controls in 48 hours at charge ratio (+/-) of 20:1 for R9 
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